Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:
”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial
Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.
This is the first study that successfully completed Phase 3 for Factor XIa.
Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.
One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.
Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.
It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.
Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”
Stay informed with Hemostasis Today.
-
Apr 16, 2026, 18:27Are We Underestimating VTE After PanNET Surgery? – RPTH Journal
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58Early Diagnosis Can Change Everything in Hemophilia Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper